[ad_1]
ABU DHABI, 29th August, 2022 (WAM) — The Emirate of Abu Dhabi has witnessed the launch of a Real World Evidence (RWE) study to provide insights into the safety and efficacy of AstraZeneca’s long-acting drug. Key real-world data antibody combination Evusheld is used to protect immunocompromised patients in the United Arab Emirates from symptomatic COVID-19.
The study is one of many outcomes of a partnership declaration signed last year by the Abu Dhabi Department of Health (DoH) and AstraZeneca.
The collaboration aims to further enhance health science research and development and foster innovation in healthcare as part of DoH’s strategy to increase patient access to quality healthcare.
The EVOLVE real-world evidence study, expected to run until the end of 2023, with up to 1,000 participants, is a collaboration between AstraZeneca and Sheikh Khalifa Medical City (SKMC) Hospital in Abu Dhabi under the supervision of DoH .
Abu Dhabi is one of the first cities to receive global shipments of AstraZeneca’s long-acting antibody drug Evusheld to ensure continuity of world-class care in the country.
This multi-country prospective observational study will support at-risk populations in the United Arab Emirates and the wider Middle East and Africa region by building on the body of evidence on how Evusheld protects against the COVID-19 virus.
Dr Jamal Mohammed Al Kaabi, Abu Dhabi’s Deputy Minister of Health, said: “We are delighted to see the results of our work together with our partners around the world to position Abu Dhabi as a leading destination for healthcare and life sciences. An incubator for innovation. Thanks to its advanced infrastructure, the emirate is able to attract global partnerships with established leaders in the health and pharmaceutical sectors who have chosen Abu Dhabi as a prime destination for innovative research projects.”
Al Kaabi stressed that the health and safety of the Abu Dhabi community and the world remains the top priority of the Ministry of Health, which ensures that the latest innovations in treatment and prevention are available to all individuals with different needs and health conditions.
About 2% of the global population has a compromised immune system that is unresponsive or insufficiently responsive to COVID-19 vaccinations. These include people with cancer, certain immune diseases, people on dialysis or on immunosuppressive therapy, and others with suppressed immune systems.
Dr. Nawal Al Kaabi, Chief Medical Officer, Head of Research, SKMC and EVOLVE, said: “The risk of contracting COVID-19 is far from over, especially for immunocompromised and vulnerable populations. Real-world evidence is essential to help us better understand It is essential to understand how the virus evolves and to build additional tools to protect at-risk populations. Looking beyond the pandemic, this innovative study will complement regional efforts to improve the quality of healthcare, advance the digitization of healthcare data, and meet demand for Growing local demand – derived clinical data that captures our unique demographics.”
Eva Turgonyi, Medical Director of AstraZeneca GCC and Pakistan, commented: “As COVID-19 continues to cast a shadow around the world, it is important to continue to protect the health and safety of all members of the community, especially the most vulnerable. More vulnerable to COVID-19 -19 complications. Unfortunately, there are some patient communities where vaccination does not provide adequate protection. By collecting real data from the United Arab Emirates, we can better understand how AstraZeneca’s long-acting antibody combination Evusheld protects immunity functionally impaired patients, allowing them to return to their daily lives.”
Evusheld has been shown to significantly protect against symptomatic COVID-19 compared with placebo, with retention of neutralizing activity against Omicron and all other variants of interest to date, according to data from the PROVENT Phase III Pre-Exposure Prophylaxis Trial. It was also shown to significantly reduce the risk of severe COVID-19 or death in non-hospitalized patients with mild to moderately symptomatic infections compared to placebo. 2 Evusheld has received emergency use authorization in the United Arab Emirates, the kingdoms of Saudi Arabia, Bahrain, Qatar and Egypt, and is the only antibody therapy with emergency use authorization in the United States for the prevention of COVID-19.
Abu Dhabi proposes a pioneering model for dealing with the COVID-19 pandemic. The emirate has been recognised in global rankings for its efficiency in tackling the pandemic and ensuring the health and safety of community members, placing it at the top of the world’s cities. These efforts run parallel to the continuity of the emirate’s economic growth.
[ad_2]
Source link